Fact CheckerSign in

NCT05850156Not yet recruiting

Study of a Deformability Parameter of Red Blood Cell

Study of a Deformability Parameter of Red Blood Cell. FITRED

Source: ClinicalTrials.gov · Last updated 11 May 2023 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Sickle-cell disease is one of the most common severe monogenic disorders in the world, it results in the synthesis of abnormal hemoglobin (HbS) instead of hemoglobin A. When deoxygenated, the sickle haemoglobin (HbS) polymerizes inducing the sickling of red blood cells (RBCs) and leading to decreased deformability and increased fragility. Therefore, sickle RBCs exhibit a reduced lifespan associated with intravascular hemolysis, hemolytic anemia and low tissue oxygenation. Sickle RBCs, which exhibit abnormal adhesive properties to endothelial cells, can block the microcirculation, causing the occurrence of painful vaso-occlusive crisis (VOC), acute chest syndrome (ACS), acute and chronic organ damage (heart, lung, liver, spleen, kidney, bone…) and shortened life span. A preliminary study performed on RBC from sickle cell patients (Hb SS) has shown an alteration of a parameter measuring the overall deformability of RBCs by evaluating the nature of their movement in a shear flow. This parameter is significantly lower in sickle cell patients in steady state compared to a population of healthy individuals. The parameter is also significantly lower in sickle cell patients during VOC when compared to patient in steady state. The main objective of this study is to evaluate the performance of the method for measuring the deformability of RBCs on an experimental prototype. Measurements will be performed on blood samples from subjects with a normal hemoglobin electrophoretic profile, from heterozygous carriers of sickle cell disease and from patients with sickle cell disease. Samples from paediatric patients will also be tested to study any specificity in comparison to adult subjects.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
130 (estimated)
First submitted
28 Apr 2023
Start date
Sept 2023
Primary completion date
Sept 2026
Lead sponsor
Assistance Publique Hopitaux De Marseille
NCT number
NCT05850156

What you commit to

  • Study type: Observational
  • Planned participants: 130
  • From Sept 2023 to the primary completion date, Sept 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Effect of ambient temperature on ftt measurements
  • Effect of sample processing time on ftt measurements

Who the study is looking for

  • Repeatability of ftt (mechanical marker of deformability) measurements

Age in the registry: 6 months to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.